Trial Profile
Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Nivolumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 17 May 2023 Status changed from suspended to completed.
- 01 Feb 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.
- 20 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.